Addition Therapeutics raises $106.5M for all RNA ‘jumping gene’ therapiesnews2025-12-17T13:22:29+00:00December 17th, 2025|Endpoints News|
Hansa’s enzyme therapy flunks Phase 3 trial in rare kidney diseasenews2025-12-17T11:20:22+00:00December 17th, 2025|Endpoints News|
GSK wins FDA approval for long-acting asthma drugnews2025-12-17T00:21:14+00:00December 17th, 2025|Endpoints News|
Harbour makes $90M upfront deal with Bristol Myers for new antibodiesnews2025-12-17T00:03:06+00:00December 17th, 2025|Endpoints News|
DBV charts new path to market peanut allergy patch after Phase 3 successnews2025-12-16T21:12:26+00:00December 16th, 2025|Endpoints News|
Makary walks back talk of Covid-19 vaccine risk amid internal FDA debatenews2025-12-16T20:05:09+00:00December 16th, 2025|Endpoints News|
Verge Genomics’ ALS drug fails as biotech shifts to partner modelnews2025-12-16T20:04:38+00:00December 16th, 2025|Endpoints News|
Mythic Therapeutics shuts down, ends ADC trial as funding dries upnews2025-12-16T18:51:01+00:00December 16th, 2025|Endpoints News|
Nektar’s immunology drug misses in Phase 2b, execs cite enrollment errorsnews2025-12-16T16:28:59+00:00December 16th, 2025|Endpoints News|
Pfizer bets big on obesity to offset major patent cliffnews2025-12-16T16:16:07+00:00December 16th, 2025|Endpoints News|
